Beijing based venture capital firm investing in pharmaceutical and biotechnology companies
Sherpa Venture Capital is a Beijing based venture capital firm investing in pharmaceutical and biotechnology companies. The firm focuses on pharmaceuticals, GeneTech, MedTech, drug discovery/delivery, laboratory services, medical services, and logistics. As of December 2019, the firm has made 12 investments with ten portfolio companies. Its portfolio companies include Immunochina, Yosemite Clinic, Hongyun Biology, Joinhealth Technology, Singleron Biotechnologies, Hui-Gene Therapeutics, and EpimAb Biotherapeutics.
Sherpa Venture Capital is a Beijing based venture capital firm investing in pharmaceutical and biotechnology companies. The firm focuses on pharmaceuticals, GeneTech, MedTech, drug discovery/delivery, laboratory services, medical services, and logistics. As of December 2019, the firm has made 12 investments with ten portfolio companies. Its portfolio companies include Immunochina, Yosemite Clinic, Hongyun Biology, Joinhealth Technology, Singleron Biotechnologies, Hui-Gene Therapeutics, and EpimAb BiotherapeuticsEpimAb Biotherapeutics.
Sherpa Venture Capital is a Beijing based venture capital firmventure capital firm investing in pharmaceutical and biotechnology companies. The firm focuses on pharmaceuticals, GeneTech, MedTech, drug discovery/delivery, laboratory services, medical services, and logistics. As of December 2019, the firm has made 12 investments with ten portfolio companies. Its portfolio companies include Immunochina, Yosemite Clinic, Hongyun Biology, Joinhealth Technology, Singleron Biotechnologies, Hui-Gene Therapeutics, and EpimAb Biotherapeutics.
Beijing based venture capital firm investing in pharmaceutical and biotechnology companies
Sherpa Venture Capital is a Beijing based venture capital firm investing in pharmaceutical and biotechnology companies. The firm focuses on pharmaceuticals, GeneTech, MedTech, drug discovery/delivery, laboratory services, medical services, and logistics. As of December 2019, the firm has made 12 investments with ten portfolio companies. Its portfolio companies include Immunochina, Yosemite Clinic, Hongyun Biology, Joinhealth Technology, Singleron Biotechnologies, Hui-Gene Therapeutics, and EpimAb Biotherapeutics.